| Patient | Paul Robeson |
|---|---|
| Date of birth | 1967-04-09 |
| Identifiers | MRN HR-ML048-SYN; SSN (made up) 000-48-2647 |
| Document date | 2026-10-05 |
| Author | Theodore Bankole-Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Mr. Robeson is a 59-year-old singer and actor with recurrent major depression who comes for the preventive visit booked in the spring. Six weeks ago aripiprazole was added to venlafaxine 225 mg; he has taken 5 mg each morning for four weeks. He sleeps about six and a half hours, his energy and interest have come back, and he practices every morning and sang at two community gatherings last month. He has noticed no restlessness, stiffness or tremor; his weight is up 1.4 kg in six weeks. The cough from the summer cleared within three weeks. He continues weekly behavioral activation and is planning a small recital. He has had no thoughts of suicide. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 59 |
| Depression | PHQ-9 6 on venlafaxine and aripiprazole |
| Side effects | No restlessness or movement problems; weight up 1.4 kg |
| Safety | No thoughts of suicide; safety plan in place |
Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with him by Dr. Bankole-Ashworth. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good and improving |
| Psychosocial | Persecution and loss of income remain his main stresses; he feels stronger in facing them; supported by friends and his therapist |
| Substance use | AUDIT-C 1 at intake, unchanged; no drug use |
| Tobacco | Never smoked |
| Physical activity | Walks 40 minutes most mornings; swimming twice a week again |
| Nutrition | Regular meals; more vegetables and less fried food since the lipid results |
| Sleep | About six and a half hours; no snoring reported; STOP-BANG 2 |
| Safety | No firearm at home; seat belt always; medicines kept in a locked box |
| Sexual health | One partner; no concerns |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; weight up 1.4 kg in six weeks |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | Voice clear; no hearing loss |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | Cough gone |
| Gastrointestinal | Negative | No change in bowel habit or bleeding |
| Genitourinary | Negative | No difficulty passing urine; no nighttime frequency |
| Musculoskeletal | Negative | No joint pain |
| Neurological | Negative | No tremor, stiffness or restlessness |
| Integumentary | Negative | No rash |
| Psychiatric | Positive | Mild low mood on some days; no thoughts of suicide; PHQ-9 6 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg tablet, one tablet each morning | 50 mg each morning for two weeks | Oral route | 2026-03-12 to 2026-03-25 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning | 100 mg each morning | Oral route | 2026-03-26 to 2026-04-19 | completed | S |
| Sertraline 50 mg tablets, three tablets (150 mg) each morning | 150 mg each morning for two weeks | Oral route | 2026-04-20 to 2026-05-03 | completed | S |
| Sertraline 100 mg tablets, two tablets (200 mg) each morning | 200 mg each morning | Oral route | 2026-05-04 to 2026-06-07 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning for one week, then stop | 100 mg each morning for one week during the switch | Oral route | 2026-06-08 to 2026-06-14 | completed | S |
| Venlafaxine extended-release 75 mg capsule, one capsule each morning with food | 75 mg each morning for one week | Oral route | 2026-06-08 to 2026-06-14 | completed | S |
| Venlafaxine extended-release 150 mg capsule, one capsule each morning with food | 150 mg each morning for three weeks | Oral route | 2026-06-15 to 2026-07-05 | completed | S |
| Venlafaxine extended-release 75 mg capsules, three capsules (225 mg) each morning with food | 225 mg each morning; 30-day supply at a time | Oral route | 2026-07-06 | active | S |
| Aripiprazole 2 mg tablet, one tablet each morning | 2 mg each morning for two weeks | Oral route | 2026-08-24 to 2026-09-06 | completed | S |
| Aripiprazole 5 mg tablet, one tablet each morning | 5 mg each morning | Oral route | 2026-09-07 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-05 | Body height | 190 | cm | S |
| 2026-10-05 | Body weight | 102.4 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 28.4 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 72 | /min | S |
| 2026-10-05 | Respiratory rate | 14 | /min | S |
| 2026-10-05 | Body temperature | 36.6 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 102.4 kg, BMI 28.4; blood pressure 130/80 |
| Neck | No lymph nodes; thyroid normal |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Soft; no mass |
| Neurological | No tremor, rigidity or abnormal movements; abnormal involuntary movement examination normal; no akathisia |
| Psychiatric | Warm and engaged; affect fuller; speech at a normal pace |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arranged | resolved | confirmed | R53.83 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D). |
| Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview) | active | confirmed | F33.2 | S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted. |
| Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusion | active | confirmed | Z60.5 | S — Synthetic coding of his documented persecution as a social determinant of his depression. |
| Acute bronchitis after a cold, without signs of pneumonia; treated without antibiotics and without dextromethorphan or decongestants because of venlafaxine; resolved | resolved | confirmed | J20.9 | S — Synthetic intercurrent illness; not a historical claim. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 130/80 mmHg; watched on venlafaxine |
| Depression screening and follow-up | Completed today | PHQ-9 6 under treatment; item 9 scored 0 |
| Unhealthy alcohol use screening | Up to date | AUDIT-C 1 at intake; no change |
| Tobacco use | Completed today | Never smoked |
| Colorectal cancer screening | Ordered | No earlier screening; he chose a yearly FIT over colonoscopy; kit given today |
| Prostate cancer screening | Due | Shared decision due: he had prostate surgery about two years ago whose reason is not in this chart; records requested before discussing PSA testing |
| Lipid screening and statin assessment | Completed today | Total cholesterol 204, HDL 46, LDL 132 mg/dL six weeks ago; pooled cohort ten-year risk about 9 percent; statin offered after discussion; he chose diet and activity first, to revisit in a year |
| Diabetes screening | Up to date | A1c 5.6% six weeks ago; repeat at twelve weeks of aripiprazole |
| Lung cancer screening | Not indicated | Never smoked |
| HIV screening | Up to date | Negative at intake |
| Hepatitis C screening | Ordered | Once for adults; drawn today |
| Hepatitis B screening | Ordered | Once for all adults; drawn today; vaccination to follow if not immune |
| Influenza vaccine | Completed today | Seasonal dose |
| Pneumococcal vaccine | Completed today | PCV20, recommended from age 50 |
| Zoster vaccine | Completed today | Recombinant vaccine dose 1 of 2 |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap six years ago on his card |
| COVID-19 vaccine | Due | Discussed; he will decide at the next visit |
| Hepatitis B vaccine | Due | After the screening result, if not immune |
Immunizations given today: Influenza vaccine, inactivated, trivalent, preservative-free; Pneumococcal conjugate vaccine, 20-valent (PCV20); Zoster vaccine, recombinant, dose 1 of 2 [S]
Guideline basis: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Colorectal Cancer: Screening (2021); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026)
Follow-up: Mood review with weight in two weeks, at eight weeks of aripiprazole; twelve-week metabolic tests. FIT result and screening results by phone. Second zoster dose in two to six months. Call or text 988 at any time in a crisis. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent. He wants full treatment of any illness. He named a health care agent, recorded in the confidential part of the chart and not named here. He asked that any future decision about ECT be his own, made with his own informed consent while he has capacity; this was recorded as his stated preference. To be revisited yearly. [S]